Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OT0X95YA)

DOT Name Protein cramped-like (CRAMP1)
Synonyms Cramped chromatin regulator homolog 1; Hematological and neurological expressed 1-like protein
Gene Name CRAMP1
Related Disease
Atrial fibrillation ( )
Epilepsy ( )
Hepatocellular carcinoma ( )
Neoplasm ( )
Non-small-cell lung cancer ( )
Triple negative breast cancer ( )
UniProt ID
CRML_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MTVKLGDGGSGEDGLKKLGKRAADEESLEGEGAGGADAAEESSGTKRDEKTPRAGADGPP
APPGAPQAPSPPQGSPQDQHHFLRSSVRPQSKRPRKDPPSAVGSGNAGGSGPRGKGAEGG
GSSSGNVSGVAPAAPAGGSRSSSRNLGSSGGEKEEGKKVRRQWESWSTEDKNTFFEGLYE
HGKDFEAIQNNIALKYKKKGKPASMVKNKEQVRHFYYRTWHKITKYIDFDHVFSRGLKKS
SQELYGLICYGELRKKIGGCMDDKNATKLNELIQVGATTVRYKGRNLRIKAPMCRALKKL
CDPDGLSDEEDQKPVRLPLKVPIELQPRNNHAWARVQSLAQNPRLRMIVELHRKVSSLIE
FLKQKWALHEVRVRKTLEERQLQDSCSAPMQEKVTLHLFPGENCTLTPLPGVARVVHSKA
FCTVHWQEGGRCKQSAKDAHVLPPAQILGIQSGQGTARGQVKCPRSGAEGKGVGRPPPAA
DALQSSGESSPESAPGEGAALSLSSPDAPDRPPPRHQDTGPCLEKTPAEGRDSPTREPGA
LPCACGQLPDLEDELSLLDPLPRYLKSCQDLIVPEQCRCADTRPGSEQPPLGGAASPEVL
APVSKEAADLAPTGPSPRPGPGLLLDVCTKDLADAPAEELQEKGSPAGPPPSQGQPAARP
PKEVPASRLAQQLREEGWNLQTSESLTLAEVYLMMGKPSKLQLEYDWLGPGRQDPRPGSL
PTALHKQRLLSCLLKLISTEVNPKLALEANTISTASVRPAQEEQSMTPPGKVVTVSSRSP
RCPRNQASLRSSKTFPPSSAPCSSGLRNPPRPLLVPGPSSTGSNDSDGGLFAVPTTLPPN
SRHGKLFSPSKEAELTFRQHLNSISMQSDFFLPKPRKLRNRHLRKPLVVQRTLLPRPSEN
QSHNVCSFSILSNSSVTGRGSFRPIQSSLTKAALSRPIVPKVLPPQATSHLASAIDLAAT
SAGILSGNPLPALDTEGLSGISPLSSDEVTGAISGQDSTGTHQDGDTLPTVGGSDPFVSI
PSRPEQEPVADSFQGSSVLSLSELPKAPLQNGLSIPLSSSESSSTRLSPPDVSALLDISL
PGPPEDALSQGEPATHISDSIIEIAISSGQYGEGVPLSPAKLNGSDSSKSLPSPSSSPQP
HWIASPTHDPQWYPSDSTDSSLSSLFASFISPEKSRKMLPTPIGTNSGTSLLGPSLLDGN
SRDSFVSRSLADVAEVVDSQLVCMMNENSIDYISRFNDLAQELSIAEPGRREALFDGGGG
GPAVSDLSQ

Molecular Interaction Atlas (MIA) of This DOT

6 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Atrial fibrillation DIS15W6U Strong Genetic Variation [1]
Epilepsy DISBB28L Strong Genetic Variation [2]
Hepatocellular carcinoma DIS0J828 Strong Biomarker [3]
Neoplasm DISZKGEW Strong Altered Expression [4]
Non-small-cell lung cancer DIS5Y6R9 Strong Biomarker [4]
Triple negative breast cancer DISAMG6N Strong Biomarker [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Disease(s)
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
5 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Valproate DMCFE9I Approved Valproate decreases the expression of Protein cramped-like (CRAMP1). [6]
Ciclosporin DMAZJFX Approved Ciclosporin increases the expression of Protein cramped-like (CRAMP1). [7]
Doxorubicin DMVP5YE Approved Doxorubicin decreases the expression of Protein cramped-like (CRAMP1). [8]
Cisplatin DMRHGI9 Approved Cisplatin decreases the expression of Protein cramped-like (CRAMP1). [9]
Deguelin DMXT7WG Investigative Deguelin decreases the expression of Protein cramped-like (CRAMP1). [12]
------------------------------------------------------------------------------------
2 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
PMID28870136-Compound-52 DMFDERP Patented PMID28870136-Compound-52 affects the phosphorylation of Protein cramped-like (CRAMP1). [10]
Bisphenol A DM2ZLD7 Investigative Bisphenol A decreases the methylation of Protein cramped-like (CRAMP1). [11]
------------------------------------------------------------------------------------

References

1 Biobank-driven genomic discovery yields new insight into atrial fibrillation biology.Nat Genet. 2018 Sep;50(9):1234-1239. doi: 10.1038/s41588-018-0171-3. Epub 2018 Jul 30.
2 GWAS identifies two susceptibility loci for lamotrigine-induced skin rash in patients with epilepsy.Epilepsy Res. 2015 Sep;115:88-94. doi: 10.1016/j.eplepsyres.2015.05.014. Epub 2015 Jun 2.
3 HN1L-mediated transcriptional axis AP-2/METTL13/TCF3-ZEB1 drives tumor growth and metastasis in hepatocellular carcinoma.Cell Death Differ. 2019 Nov;26(11):2268-2283. doi: 10.1038/s41418-019-0301-1. Epub 2019 Feb 18.
4 Overexpression of HN1L promotes cell malignant proliferation in non-small cell lung cancer.Cancer Biol Ther. 2017 Nov 2;18(11):904-915. doi: 10.1080/15384047.2017.1385678. Epub 2017 Oct 20.
5 HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway.Stem Cell Reports. 2018 Jan 9;10(1):212-227. doi: 10.1016/j.stemcr.2017.11.010. Epub 2017 Dec 14.
6 Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
7 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
8 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
9 Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
10 Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
11 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
12 Neurotoxicity and underlying cellular changes of 21 mitochondrial respiratory chain inhibitors. Arch Toxicol. 2021 Feb;95(2):591-615. doi: 10.1007/s00204-020-02970-5. Epub 2021 Jan 29.